Naohiko Anzai

Has grant

Country flagJapan

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

脳虚血耐性におけるアストロサイト由来乳酸の役割の解明

Open Date: 2022-04-01

Close Date: 2025-03-31

Grant: Close

高齢時の体液貯留かつ低栄養を惹起する鍵分子はバソプレシンなのか?

Open Date: 2022-04-01

Close Date: 2025-03-31

Grant: Close

Development of new BNCT sensitizer based on molecular chirality recognition of amino acid transporter LAT

Open Date: 2021-07-09

Close Date: 2023-03-31

Grant: Close

Transporter-targeted drug development against urological cancers by utilizing liquid biopsy and AI

Open Date: 2021-04-01

Close Date: 2024-03-31

Grant: Close

抗酸化作用を介した膵内外分泌から紐解く食品含有1,5-AGの生理機能

Open Date: 2020-04-01

Close Date: 2023-03-31

Articles (6)

L‐type amino acid transporter 1 (LAT1) is specifically expressed in many malignancies, contributes to the transport of essential amino acids, such as leucine, and regulates the mammalian target of rapamycin (mTOR) signaling pathway. We investigated the expression profile and functional role of LAT1 in prostate cancer using JPH203, a specific inhibitor of LAT1. LAT1 was highly expressed in castration‐resistant prostate cancer (CRPC) cells, including C4‐2 and PC‐3 cells, but its expression level was low in castration‐sensitive LNCaP cells. JPH203 significantly inhibited [ 14 C] leucine uptake in CRPC cells but had no effect in LNCaP cells. JPH203 inhibited the proliferation, migration, and invasion of CRPC cells but not of LNCaP cells. In C4‐2 cells, Cluster of differentiation (CD) 24 was identified by RNA sequencing as a novel downstream target of JPH203. CD24 was downregulated in a JPH203 concentration‐dependent manner and suppressed activation of the Wnt/β‐catenin signaling pathway. Furthermore, an in vivo study showed that JPH203 inhibited the proliferation of C4‐2 cells in a castration environment. The results of this study indicate that JPH203 may exert its antitumor effect in CRPC cells via mTOR and CD24.

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Hiroto Hatakeyama

Professor

Chiba University

JAPAN
View details

Hiromi Sato

Chiba University

JAPAN
View details

Akihiro Hisaka

-

JAPAN
View details

Shinichi Sakamoto

Associate Professor

Chiba University Graduate School of Medicine

JAPAN
View details

Yuri Hirayama

Chiba University

JAPAN
View details

Yoshihiro Onouchi

Professor

Chiba University Graduate School of Medicine

JAPAN
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.